Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sedana Medical AB (publ) (SEDANA.ST)
Danderyd, SE
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.33% | -5.71% | -8.82% | +7.05% | -6.83% | -12.22% | -19.98% | -68.44% | -88.66% | +58.15% | +58.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+12.0% ★ Q1'26: -7.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-445.5% Q1'26: +84.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-19.7% Q1'26: +4.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-16.1% Q1'26: -9.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-4.0% Q1'26: -2.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.46× Q1'26: 0.86× (vs Q1'25)
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
40.43M
est: 40.04M (+1.0%)
|
57.90M
est: 58.20M (-0.5%)
|
71.65M
est: 70.66M (+1.4%)
|
141.77M
est: 137.10M (+3.4%)
|
159.15M
est: 146.55M (+8.6%)
|
122.87M
est: 117.11M (+4.9%)
|
153.87M
est: 168.68M (-8.8%)
|
178.75M
est: 178.63M (+0.1%)
|
200.23M
est: 199.45M (+0.4%)
|
206.00M
206.00M – 206.00M
+3.3% YoY
|
259.00M
259.00M – 259.00M
+25.7% YoY
|
331.50M
318.24M – 344.76M
+28.0% YoY
|
| EBITDA |
-12.5K
est: -10.54M (+99.9%)
|
-2.87M
est: -15.32M (+81.3%)
|
-13.07M
est: -18.60M (+29.7%)
|
-17.22M
est: -36.09M (+52.3%)
|
-49.10M
est: -38.58M (-27.3%)
|
-64.87M
est: -30.83M (-110.4%)
|
-51.67M
est: -42.02M (-23.0%)
|
-4.03M
est: -44.49M (+90.9%)
|
-10.12M
est: -49.68M (+79.6%)
|
-51.31M
-51.31M – -51.31M
-3.3% YoY
|
-64.51M
-64.51M – -64.51M
-25.7% YoY
|
-82.57M
-85.88M – -79.27M
-28.0% YoY
|
| EBIT |
-2.76M
est: -12.46M (+77.8%)
|
-6.52M
est: -18.11M (+64.0%)
|
-16.89M
est: -21.99M (+23.2%)
|
-23.92M
est: -42.66M (+43.9%)
|
-57.13M
est: -45.61M (-25.3%)
|
-72.68M
est: -36.44M (-99.4%)
|
-58.80M
est: -52.22M (-12.6%)
|
-9.77M
est: -55.30M (+82.3%)
|
-32.16M
est: -61.74M (+47.9%)
|
-63.77M
-63.77M – -63.77M
-3.3% YoY
|
-80.18M
-80.18M – -80.18M
-25.7% YoY
|
-102.63M
-106.73M – -98.52M
-28.0% YoY
|
| Net Income |
-3.88M
est: -9.28M (+58.3%)
|
-6.87M
est: -12.67M (+45.8%)
|
-16.36M
est: -19.69M (+16.9%)
|
-27.14M
est: -16.46M (-64.9%)
|
-57.97M
est: -66.73M (+13.1%)
|
-73.51M
est: -55.81M (-31.7%)
|
-59.61M
est: -41.47M (-43.7%)
|
-10.67M
est: -30.89M (+65.4%)
|
-59.24M
est: -55.75M (-6.3%)
|
-24.34M
-24.34M – -24.34M
+56.3% YoY
|
-12.42M
-12.42M – -12.42M
+49.0% YoY
|
10.93M
10.93M – 10.93M
+188.0% YoY
|
| SGA |
16.83M
est: 39.39M (-57.3%)
|
21.65M
est: 57.26M (-62.2%)
|
56.32M
est: 69.52M (-19.0%)
|
102.42M
est: 134.88M (-24.1%)
|
148.31M
est: 144.18M (+2.9%)
|
169.94M
est: 115.22M (+47.5%)
|
154.74M
est: 167.63M (-7.7%)
|
156.60M
est: 177.53M (-11.8%)
|
154.66M
est: 198.22M (-22.0%)
|
204.73M
204.73M – 204.73M
+3.3% YoY
|
257.40M
257.40M – 257.40M
+25.7% YoY
|
329.46M
316.27M – 342.64M
+28.0% YoY
|
| EPS |
-0.06
est: -0.09 (+39.2%)
|
-0.09
est: -0.13 (+29.7%)
|
-0.20
est: -0.20 (-0.9%)
|
-0.30
est: -0.17 (-81.1%)
|
-0.62
est: -0.67 (+7.7%)
|
-0.74
est: -0.56 (-31.7%)
|
-0.60
est: -0.42 (-43.7%)
|
-0.11
est: -0.31 (+64.6%)
|
-0.60
est: -0.56 (-6.9%)
|
-0.25
-0.25 – -0.25
+56.3% YoY
|
-0.13
-0.13 – -0.13
+49.0% YoY
|
0.11
0.11 – 0.11
+188.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 52.9K | 0.40% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 6.7K | 0.30% |
| 3 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 264.9K | 0.03% |
| 4 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 3.1K | 0.07% |
| 5 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 58.5K | 0.22% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 31.1K | 0.28% |
| 7 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 3.0K | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Johannes Doll | Group CEO & President | 8M | male |
| David Bergstrom | Vice President of Operations, Supply and R&D | — | male |
| Jessica Westfal | Vice President of Regulatory Affairs and QA | — | male |
| Johan G. Spetz | Chief Financial Officer | — | male |
| Karolin Sjosten | Vice President of Human Resources | — | female |
| Karolina Vilval | General Counsel | — | female |
| Linda Frölén | Head of Group Finance | — | female |
| Peter Sackey | Chief Medical Officer | — | male |
| Sinead Renouf-Wood | Vice President of Marketing | — | female |
| Anders Ersson | Head of International Markets | — | — |
| Stefan Krisch | Supply Chain & Manufacturing Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SEDANA.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
